Keele Research Repository

Article

Rifkin-Zybutz, R, MacNeill, S, Davies, SJ, Dickens, C, Campbell, J, Anderson, IM, Chew-Graham, CA ORCID: https://orcid.org/0000-0002-9722-9981, Peters, TJ, Lewis, G, Wiles, N and Kessler, D (2020) Does anxiety moderate the effectiveness of mirtazapine in patients with treatment-resistant depression? A secondary analysis of the MIR trial. Journal of Psychopharmacology, 34 (12). 1342 - 1349.

Kessler, DS, MacNeil, SJ, Tallon, D, Lewis, G, Peters, TJ, Hollingworth, W, Round, J, Burns, A, Chew-Graham, CA, Anderson, IM, SHEPHERD, T, Campbell, J, Dickens, CM, Carter, M, Jenkinson, C, Macleod, U, Gibson, H, Davies, S and Wiles, NJ (2018) MIRtazapine added to SSRIs or SNRIs for Treatment Resistant Depression in Primary Care: a placebo controlled randomised trial (MIR). BMJ, 363.

Kessler, DS, MacNeill, SJ, Tallon, D, Lewis, G, Peters, TJ, Hollingworth, W, Round, J, Burns, A, Chew-Graham, CA, Anderson, IM, Shepherd, T, Campbell, J, Dickens, CM, Carter, M, Jenkinson, C, Macleod, U, Gibson, H, Davies, S and Wiles, NJ (2018) Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). BMJ, 363. k4218 - ?.

Tallon, D, Wiles, N, Campbell, J, Chew-Graham, CA, Dickens, C, Macleod, U, Peter, TJ, Lewis, G, Anderson, IM, Gilbody, S, Hollingworth, W, Davies, SJ and Kessler, D (2016) Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial. Trials, 17 (1). p. 66.